Home> For patients & carers> AML Delphi Survey Project: Developing a Core Outcome Set for Acute Myeloid Leukemia

AML Delphi Survey Project: Developing a Core Outcome Set for Acute Myeloid Leukemia

March 08, 2020 21:17 - x 00, 0 - 00:00

One of HARMONY’s aims is to increase consistency in future clinical trials therefore allowing for the results achieved to be compared and combined creating increased value to the hematological community. To do this, clinical trials need to use consistent core outcomes, please help which outcomes should be chosen. HARMONY researchers are at this time compiling a set of the most important outcomes for AML by consulting a panel of stakeholders. 


To participate in the AML Delphi survey open this link:

https://delphimanager.liv.ac.uk/HARMONY


What is a Core Outcome Set (COS)?

A COS is a minimum set of outcomes that should be collected and reported in future clinical trials. A COS will be defined by several stakeholder groups including patients, clinicians, health authorities and the pharmaceutical industry.  Of course, researchers may include additional outcomes in a particular trial. A COS functions as an international standard to evaluate treatments in clinical trials and other research settings (e.g., registry and observational studies) to assess real world data. Implementing a COS will improve the comparability of clinical trials and observational studies, improve the consistency of reporting, and reduce selective reporting bias. In addition, the COS can be incorporated in clinical guidelines and be used to improve patient management.


A Pilot Study Involving Acute Myeloid Leukemia (AML)

The team of HARMONY Work Package 2  is coordinating a survey to define a COS for AML. AML is the most common Acute Leukemia in adults. Despite recent scientific advances, AML cure rates remain poor compared to other hematologic malignancies. In addition to accelerating clinical research, defining a COS may help to improve the clinical management of AML. In the pilot study, HARMONY will focus on outcomes for AML in patients 18 years and older.

HARMONY uses the Delphi method for this survey. This method will help to ensure that the COS represents the priorities of clinicians, industry, health authorities, and patients alike. We will start similar projects for the other Hematologic Malignancies that are being studied by HARMONY.  


The HARMONY Alliance: public-private partnership for big data in hematology

The term ‘Big Data’ is more commonly being used by professionals and non-professional; such data are described as having ‘transformative potential’ – but what exactly is 'Big Data' in healthcare, how and why is HARMONY using it and what does it mean for people with Hematologic Malignancies? Watch our short video series to find out >

 


Receive the latest news. Click here to subscribe!